Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Haas

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2018
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registryPaulus Stefan Rommer, Kerstin Eichstädt, David Ellenberger, et al.
Scientific Reports|June 26, 2021
Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registryLisa-Marie Ohle, David Ellenberger, Peter Flachenecker, et al.
Journal of Neurology|January 4, 2022
Long-term real-world effectiveness and safety of fingolimod over 5 years in GermanyTjalf Ziemssen, Michael Lang, Stephan Schmidt, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 19, 2019
Real-world persistence and benefit-risk profile of fingolimod over 36 months in GermanyTjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Journal of Neuroimmunology|December 3, 2014
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomicsThomas Berger, Christian Jacobi, Judith Haas, et al.
International Journal of MS Care|March 7, 2018
Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy DatabaseMagnhild Sandberg-Wollheim, Orit Neudorfer, Augusto Grinspan, et al.
BMC Neurology|July 14, 2016
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumabTjalf Ziemssen, Achim Gass, Jens Wuerfel, et al.
Journal of Clinical Medicine|June 10, 2023
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational StudyNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Vaccines|December 23, 2023
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational StudyFiras Fneish, Niklas Frahm, Melanie Peters, et al.
Neurology and Therapy|January 12, 2022
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS RegistryNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2018
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registryPaulus Stefan Rommer, Kerstin Eichstädt, David Ellenberger, et al.
Scientific Reports|June 26, 2021
Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registryLisa-Marie Ohle, David Ellenberger, Peter Flachenecker, et al.
Journal of Neurology|January 4, 2022
Long-term real-world effectiveness and safety of fingolimod over 5 years in GermanyTjalf Ziemssen, Michael Lang, Stephan Schmidt, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 19, 2019
Real-world persistence and benefit-risk profile of fingolimod over 36 months in GermanyTjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Journal of Neuroimmunology|December 3, 2014
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomicsThomas Berger, Christian Jacobi, Judith Haas, et al.
International Journal of MS Care|March 7, 2018
Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy DatabaseMagnhild Sandberg-Wollheim, Orit Neudorfer, Augusto Grinspan, et al.
BMC Neurology|July 14, 2016
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumabTjalf Ziemssen, Achim Gass, Jens Wuerfel, et al.
Journal of Clinical Medicine|June 10, 2023
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational StudyNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Vaccines|December 23, 2023
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational StudyFiras Fneish, Niklas Frahm, Melanie Peters, et al.
Neurology and Therapy|January 12, 2022
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS RegistryNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Pageof 5